Impact of Subtotal Parathyroidectomy on Clinical Parameters and Quality of Life in Hemodialysis Patients with Secondary Hyperparathyroidism
- PMID: 31884736
- PMCID: PMC6935777
- DOI: 10.3803/EnM.2019.34.4.367
Impact of Subtotal Parathyroidectomy on Clinical Parameters and Quality of Life in Hemodialysis Patients with Secondary Hyperparathyroidism
Abstract
Background: Impairment of quality of life (QOL) is a key clinical characteristic of patients with end-stage renal disease (ESRD), and can be especially severe in the presence of secondary hyperparathyroidism (SHPT). Despite the proven success of parathyroidectomy (PTX) in controlling biochemical parameters in patients with severe SHPT, evidence is lacking regarding the effects of PTX on various clinical outcomes, including QOL.
Methods: Twenty ESRD patients on maintenance hemodialysis with SHPT who underwent subtotal PTX were included in an observational longitudinal study. All studied patients underwent history-taking, clinical examinations, and laboratory investigations, including a complete blood count and measurements of serum calcium, phosphorus, magnesium, parathyroid hormone (PTH), and albumin levels preoperatively and at 3 months postoperatively. QOL was assessed before surgery and at 3 months after surgery using the Kidney Disease Quality of Life 36-Item Short-Form instrument.
Results: After PTX, significant decreases in serum PTH and phosphorus levels were observed, as well as a significant increase in serum magnesium levels. Significant weight gain and improvements of QOL were also detected postoperatively.
Conclusion: Subtotal PTX seems to be an efficient alternative to medical management in uncontrolled cases of SHPT, as it is capable of controlling the biochemical derangements that occur in hyperparathyroidism. Furthermore, PTX had a beneficial effect on clinical outcomes, as shown by weight gain and improvements in all QOL scales.
Keywords: Hyperparathyroidism, secondary; Parathyroidectomy; Quality of life; Renal dialysis.
Copyright © 2019 Korean Endocrine Society.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Similar articles
-
Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism.Int Urol Nephrol. 2015 Nov;47(11):1871-7. doi: 10.1007/s11255-015-1106-x. Epub 2015 Sep 16. Int Urol Nephrol. 2015. PMID: 26377492
-
Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism.Ren Fail. 2019 Nov;41(1):921-929. doi: 10.1080/0886022X.2019.1666724. Ren Fail. 2019. PMID: 31573378 Free PMC article.
-
Quality of life after surgery in secondary hyperparathyroidism, comparing subtotal parathyroidectomy with total parathyroidectomy with immediate parathyroid autograft: Prospective randomized trial.Surgery. 2018 Nov;164(5):978-985. doi: 10.1016/j.surg.2018.06.032. Epub 2018 Aug 3. Surgery. 2018. PMID: 30082137 Clinical Trial.
-
Long-term outcomes and management considerations after parathyroidectomy in the dialysis patient.Semin Dial. 2019 Nov;32(6):541-552. doi: 10.1111/sdi.12833. Epub 2019 Jul 16. Semin Dial. 2019. PMID: 31313380 Review.
-
Resurgence of parathyroidectomy: evidence and outcomes.Curr Opin Nephrol Hypertens. 2017 Jul;26(4):243-249. doi: 10.1097/MNH.0000000000000326. Curr Opin Nephrol Hypertens. 2017. PMID: 28375871 Review.
Cited by
-
Effect of Parathyroidectomy on Quality of Life Among Patients Undergoing Dialysis.Int J Gen Med. 2022 Feb 5;15:1185-1192. doi: 10.2147/IJGM.S354145. eCollection 2022. Int J Gen Med. 2022. PMID: 35153509 Free PMC article.
-
Abnormalities of serum magnesium levels in dialysis patients undergoing parathyroidectomy.Updates Surg. 2024 Aug;76(4):1435-1441. doi: 10.1007/s13304-024-01790-x. Epub 2024 Mar 13. Updates Surg. 2024. PMID: 38480639
-
Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.Front Public Health. 2021 Jul 21;9:712027. doi: 10.3389/fpubh.2021.712027. eCollection 2021. Front Public Health. 2021. PMID: 34368073 Free PMC article.
References
-
- Rodriguez M, Lorenzo V. Parathyroid hormone, a uremic toxin. Semin Dial. 2009;22:363–368. - PubMed
-
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl. 2009;(113):S1–S130. - PubMed
-
- Trombetti A, Stoermann C, Robert JH, Herrmann FR, Pennisi P, Martin PY, et al. Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World J Surg. 2007;31:1014–1021. - PubMed
-
- Valente-Da-Silva HG, Maya MCA, Moreira AS. Parathyroidectomy in chronic kidney disease: effects on weight gain and on quality of life improvement. Rev Col Bras Cir. 2017;44:263–269. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical